ES2097766T3 - Composiciones para la inhibicion de la formacion de hormonas proteicas y sus usos. - Google Patents

Composiciones para la inhibicion de la formacion de hormonas proteicas y sus usos.

Info

Publication number
ES2097766T3
ES2097766T3 ES90917939T ES90917939T ES2097766T3 ES 2097766 T3 ES2097766 T3 ES 2097766T3 ES 90917939 T ES90917939 T ES 90917939T ES 90917939 T ES90917939 T ES 90917939T ES 2097766 T3 ES2097766 T3 ES 2097766T3
Authority
ES
Spain
Prior art keywords
molecular weight
tnf
convertase
inhibition
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90917939T
Other languages
English (en)
Inventor
Michael P Kriegler
Carl F Perez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of ES2097766T3 publication Critical patent/ES2097766T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPUESTOS QUE TIENEN UNA ACTIVIDAD DE INHIBICION PROTEOLITICA UTIL PARA TRATAR ENFERMEDADES, EN PARTICULAR APLICADOS AL TRATAMIENTO DE SEPSIS, SIDA O ENFERMEDAD AUTOINMUNE, QUE RESULTAN DE UN INCREMENTO EN EL NIVEL DE CIRCULACION DE HORMONAS DE PROTEINA MADURAS DERIVADAS DE LA DIVISION PROTEOLITICA DE PRECURSOS DE PROHORMONAS Y METODOS PARA IDENTIFICAR COMPUESTOS QUE TIENEN UNA ACTIVIDAD DE INHIBICION DESEADO.
ES90917939T 1989-08-16 1990-06-08 Composiciones para la inhibicion de la formacion de hormonas proteicas y sus usos. Expired - Lifetime ES2097766T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39525389A 1989-08-16 1989-08-16

Publications (1)

Publication Number Publication Date
ES2097766T3 true ES2097766T3 (es) 1997-04-16

Family

ID=23562283

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90917939T Expired - Lifetime ES2097766T3 (es) 1989-08-16 1990-06-08 Composiciones para la inhibicion de la formacion de hormonas proteicas y sus usos.

Country Status (9)

Country Link
EP (2) EP0750037A3 (es)
JP (1) JP2930713B2 (es)
AT (1) ATE148992T1 (es)
AU (2) AU5940090A (es)
CA (1) CA2020700A1 (es)
DE (1) DE69029970T2 (es)
DK (1) DK0491878T3 (es)
ES (1) ES2097766T3 (es)
WO (1) WO1991002540A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586222B1 (en) 1989-08-16 2003-07-01 Chiron Corporation Recombinant PR-3 and compositions thereof
US5843693A (en) * 1989-08-16 1998-12-01 Chiron Corporation Assay method for screening for inhibitors of proTNF conversion
US5998378A (en) * 1989-08-16 1999-12-07 Chiron Corporation Compositions for the inhibition of TNF hormone formation and uses thereof
WO1992002822A1 (en) * 1990-08-06 1992-02-20 Cetus Corporation Methods for the identification of cytokine convertase inhibitors
US5795859A (en) * 1991-07-05 1998-08-18 Peptide Technology Limited Peptide which abrogates TNF and/or LPS toxicity
US6348327B1 (en) * 1991-12-06 2002-02-19 Genentech, Inc. Non-endocrine animal host cells capable of expressing variant proinsulin and processing the same to form active, mature insulin and methods of culturing such cells
JPH07508650A (ja) * 1992-06-25 1995-09-28 カイロン　コーポレーション タンパク質ホルモン形成の阻害のための組成物およびその使用
JP3517238B2 (ja) * 1992-09-09 2004-04-12 アムジェン インコーポレイテッド レトロウイルス感染の阻害
US5594106A (en) * 1993-08-23 1997-01-14 Immunex Corporation Inhibitors of TNF-α secretion
EP0749494A1 (en) 1994-03-07 1996-12-27 Chiron Corporation Compositions for the inhibition of tnf formation and uses thereof
US6406901B1 (en) 1995-06-08 2002-06-18 Immunex Corporation TNF-a converting enzyme
US5830742A (en) * 1995-06-08 1998-11-03 Immunex Corporation TNF-α converting enzyme
DK0830130T3 (da) * 1995-06-08 2004-12-20 Immunex Corp TNF-alfa-omdannende enzym
CN1310675C (zh) * 1995-07-20 2007-04-18 依默耐克斯有限公司 TNF－α转变酶
US5853977A (en) 1996-07-12 1998-12-29 Schering Corporation Mammalian TNF-α convertases
US6180402B1 (en) 1996-11-20 2001-01-30 Qlt Inc. Method for inhibiting apoptosis induced by photodynamic therapy using a cysteine or serine protease inhibitor
US7070771B1 (en) 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
US7786282B2 (en) 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US7495090B2 (en) 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB867679A (en) 1958-10-06 1961-05-10 Allied Chem Improved process for the preparation of hydrogen peroxide
GB1158829A (en) 1967-08-04 1969-07-23 Ifa Getriebewerke Brandenburg Shift Mechanism for Overdrive Arrangements
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPH0695939B2 (ja) 1983-12-02 1994-11-30 大日本製薬株式会社 ウサギ癌壊死因子をコ−ドするクロ−ン化ｄνａ
EP0148311B1 (en) 1983-12-26 1988-07-20 Asahi Kasei Kogyo Kabushiki Kaisha A novel physiologically active polypeptide
EP0155549B1 (en) 1984-03-06 1991-03-20 Dainippon Pharmaceutical Co., Ltd. Dna encoding human tumor necrosis factor and human tumor necrosis factor polypeptide
US4879226A (en) 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
GR851626B (es) 1984-07-05 1985-11-26 Genentech Inc
FI853395L (fi) 1984-09-05 1986-03-06 Cetus Corp Monoklonala antikroppar som blockerar gram-negativ bakterieendotoxin.
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4677064A (en) 1984-11-09 1987-06-30 Cetus Corporation Human tumor necrosis factor
EP0200748B1 (en) 1984-10-15 1991-02-06 Cetus Corporation Human tumor necrosis factor
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
IL88502A (en) * 1987-12-14 1993-04-04 Squibb & Sons Inc Pharmaceutical compositions containing an angiotensin converting enzyme inhibitor
GB8806339D0 (en) * 1988-03-17 1988-04-13 Hoffmann La Roche Monoclonal antibodies
AU1241000A (en) 1998-10-27 2000-05-15 Clinical Micro Sensors, Inc. Detection of target analytes using particles and electrodes

Also Published As

Publication number Publication date
EP0750037A3 (en) 1997-01-15
AU2047495A (en) 1995-10-19
EP0491878A1 (en) 1992-07-01
DE69029970T2 (de) 1997-06-19
EP0750037A2 (en) 1996-12-27
AU5940090A (en) 1991-04-03
JP2930713B2 (ja) 1999-08-03
CA2020700A1 (en) 1991-02-17
EP0491878B1 (en) 1997-02-19
DK0491878T3 (da) 1997-06-23
WO1991002540A1 (en) 1991-03-07
AU685609B2 (en) 1998-01-22
DE69029970D1 (de) 1997-03-27
JPH04507044A (ja) 1992-12-10
ATE148992T1 (de) 1997-03-15

Similar Documents

Publication Publication Date Title
ES2097766T3 (es) Composiciones para la inhibicion de la formacion de hormonas proteicas y sus usos.
DK0791571T3 (da) Benzoylderivater
DK0409472T3 (da) Knoglemorfogenetisk protein
ES2083685T3 (es) Intermediarios para la sintesis de compuestos de la 19-nor-vitamina d.
FI890311A0 (fi) Kemiska foereningar.
FI914927A0 (fi) Fungicida oxazolidinoner.
YU194491A (sh) Nove hidantoinske spojine
FI924424A0 (fi) Hjaertskyddande tokoferolanaloger.
ATE144498T1 (de) Herstellung von substituierten piperidinen
DE59003144D1 (de) Destillationsanlage zur Herstellung von Wasserstoff-Peroxid.
DE68902192D1 (de) Ethylenthioharnstoff enthaltende zusammensetzungen zur herstellung von verschleissfesten, stromlos abgeschiedenen nickel-borueberzuegen.
DK339386A (da) Aromatiske forbindelser
ATE108446T1 (de) Ringsubstituierte 2-amin-1,2,3,4-tetrahydro- naphthaline.
DE3380476D1 (en) Control of microflora and preparations therefor
ATE151435T1 (de) Neue 17,20-epoxyd derivate von pregnan, ihre verwendung zur herstellung von cortison-derivaten und zwischenprodukte dafür
PT816353E (pt) Novos derivados de coumarina, processos para a sua preparacao e sua utilizacao
DE69001589D1 (de) Ca(oh)2-zusammensetzung zur desinfektion von dentalkanaelen.
ATE215948T1 (de) Verfahren zur herstellung von mequitazin und zwischenprodukt der synthese
FI921356A (fi) Somatostatinreceptor
DE3888543D1 (de) Zusammensetzungen zur herstellung von gasdurchlässigen kontaktlinsen.
DE69109953D1 (de) Alfa-fluorocarbonsäurederivate als Zwischenprodukte zur Herstellung von Fungiziden.
DE69731090D1 (de) Thienylcyclohexan-derivte zur herstellung von thienylcyclohexylen
DE69204497D1 (de) Verfahren und Zwischenprodukte zur Herstellung von 2,2-Dimethyl-2,3-Dihydrobenzofuran-7-Carbonsäuren.
DE59203617D1 (de) Verfahren zur Herstellung von 2,4-Dichlor-5-fluorbenzonitril.
ATE186293T1 (de) Derivate von alkyl-3-oxo-alkanoaten und verfahren zur ihrer herstellung

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 491878

Country of ref document: ES